17 completed. 11 Phase 1, 4 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 11 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Rigosertib Sodium: new trials by email Literature Review of Rigosertib Sodium trials Research Report on Rigosertib Sodium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC Rigosertib Sodium, Quality-of-Life Assessment - Recessive Dystrophic Epidermolysis Bullosa | Early Phase 1 | Completed | Thomas Jefferson University | 3 | 2021-08-24 | 2025-08-01 |
| Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers rigosertib - Healthy | Phase 1 | Completed | Traws Pharma, Inc. | 6 | 2014-01-01 | 2017-06-23 |
| Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer oral rigosertib, cisplatin, Radiotherapy - Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 1 | Completed | Traws Pharma, Inc. | 2 | 2014-01-01 | 2017-06-23 |
| Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine rigosertib sodium - Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts | Phase 3 | Completed | Traws Pharma, Inc. | 67 | 2013-08-01 | 2020-06-30 |
| Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Oral rigosertib - Myelodysplastic Syndromes | Phase 2 | Completed | Traws Pharma, Inc. | 45 | 2013-07-01 | 2021-06-16 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome rigosertib - Myelodysplastic Syndrome, MDS | Phase 2 | Completed | Traws Pharma, Inc. | 82 | 2012-05-01 | 2017-06-26 |
| Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer ON 01910.Na, Gemcitabine - Metastatic Pancreatic Adenocarcinoma | Phase 3 | Completed | Traws Pharma, Inc. | 160 | 2011-05-01 | 2016-08-04 |
| Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors rigosertib - Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 68 | 2010-07-01 | 2017-06-23 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) rigosertib - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 30 | 2010-07-01 | 2017-06-26 |
| Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors ON 01910.Na, Gemcitabine - Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 10 | 2010-01-01 | 2017-06-23 |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients ON 01910.Na - Ovarian Cancer | Phase 2 | Completed | Traws Pharma, Inc. | 1 | 2009-03-01 | 2017-07-21 |
| Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors gemcitabine, ON 01910.Na - Malignant Neoplasmas, Solid Tumors | Phase 1 | Completed | Traws Pharma, Inc. | 39 | 2009-01-01 | 2017-06-23 |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) ON 01910.Na - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Completed | Traws Pharma, Inc. | 22 | 2008-10-01 | 2018-01-10 |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na - Hepatoma, Advanced Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 16 | 2008-06-01 | 2017-06-23 |
| Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin - Advanced Solid Tumors | Phase 1 | Completed | Traws Pharma, Inc. | 18 | 2008-02-01 | 2017-06-23 |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer rigosertib sodium - Advanced Cancer, Solid Tumors | Phase 1 | Completed | Traws Pharma, Inc. | 29 | 2006-08-01 | 2017-06-23 |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer rigosertib sodium - Solid Tumors, Advanced Cancer | Phase 1 | Completed | Traws Pharma, Inc. | 42 | 2006-06-01 | 2017-06-23 |
Myelodysplastic Syndromes (4) · Neoplasms (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Squamous Cell (1) · Chromosome 8, trisomy (1) · Cytopenia (1) · Epidermolysis Bullosa Dystrophica (1) · Head and Neck Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1)
Traws Pharma, Inc. (16) · Thomas Jefferson University (1)
United States (17) · France (2) · Germany (2) · Australia (1) · Denmark (1) · Hungary (1) · India (1) · Italy (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1)
Antonio Jimeno, MD, PhD (4) · Sridhar Mani, MD (3) · Steven M. Fruchtman, MD (3) · Francois Wilhelm, MD, PhD (1) · Gregory P. Sutton, MD (1) · Jorge Cortes, MD (1) · Lawrence P. Leichman, MD (1) · Lewis R. Silverman, MD (1) · Neda Nikbakht, MD, PhD (1) · Pamela N. Munster, MD (1) · Takao Ohnuma, M.D. (1) · Takao Ohnuma, MD (1) · Wells Messersmith, MD (1)
PMID 22338014, PMID 23841031, PMID 24777753, PMID 26091808, PMID 26489442, PMID 26945010, PMID 27400247, PMID 29144985